We already know that about 36% of people who get fully vaccinated by the Pfizer-BioNTech mRNA vaccine will get COVID and have symptoms and 7% will still get serious illness. The 93% prevention of serious illness is great. A full course of the Pfizer-BioNTech vaccine is 64% effective at preventing symptomatic Covid-19, according to an …
By Feb 7, 2021, Israel had administered over 5 million doses of the Pfizer vaccine which covered 60% of its population. Israel has a population 9.3 million people. The US might get to the current Israel vaccination level around May-June. Israel still had a spike in cases in February. Israel was targeting the vaccination of …
The two-dose regimen of the Moderna COVID-19 Vaccine at the 100 µg dose is expected to be protective against emerging strains detected to date. Moderna will test an additional booster dose of its COVID-19 Vaccine (mRNA-1273) to study the ability to further increase neutralizing titers against emerging strains beyond the existing primary vaccination series. Moderna …
The Moderna COVID Vaccine was created on Jan 13, 2020. This was one month before the first recorded US COVID death. Ten months was mainly spent on trials and statistical proving how effective vaccine was effective. Experts were very certain that the potential vaccines would be safe. Clearly the effectiveness testing and verification should be …
Moderna, Inc. (Nasdaq: MRNA) reported the results of its Phase 3 study of mRNA-1273 has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%. A secondary endpoint analyzed severe cases of COVID-19 and included 11 severe cases (as defined in the study protocol) in this first interim …
Elon Musk is 49 so his risks are very low with COVID. Elon is a multi-billionaire and will be able to get the best treatments. Having two positive tests out of four then this is 99% likely that Elon has COVID. Early stage COVID rapid tests only have false positives 10% of the time. False …
Pfizer and BioNTech, announced positive efficacy results from our Phase 3, late-stage study of our potential COVID-19 vaccine. The vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis. The results demonstrate that our mRNA-based vaccine can help …
The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for investigational convalescent plasma for the treatment of COVID-19 in hospitalized patients. The tests on 70,000 people suggest that the blood transfusion can reduced COVID-19 mortality by 35%. This procedure is transferring antibodies in the blood of people who were infected with COVID-19 …
Written and Researched by Evan Wang (15), Certificate of Distinction by placing in the top 0.57% of more than 19,000 students (top 100 out of 19000) writing the Fermat Math contest globally. Motivation As school comes back into session, there seems to not be much actionable advice. The advice that I have found is vague, …
Dr. Scott Gottlieb, member of the boards of Pfizer and biotech company Illumina and former FDA commissioner expects that any coronavirus vaccine that proves to be safe and effective will still probably only provide immunity for a limited amount of time, maybe “up to a year,” former Food and Drug Administration Commissioner Dr. Scott Gottlieb …
Based on the results of the first round of COVID-19 antibody testing, the USC research team estimates that approximately 4.1% of the LA county’s adult population has an antibody to the virus. Adjusting this estimate for the statistical margin of error implies about 2.8% to 5.6% of the county’s adult population has an antibody to …